Ashland board declares regular quarterly dividend
Get Alerts ASH Hot Sheet
Join SI Premium – FREE
COVINGTON, KY, November 17, 2016 - The board of directors of Ashland Global Holdings Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.39 per share on the company's common stock. The dividend is payable December 15, 2016, to shareholders of record at the close of business on December 1, 2016. As of October 31, 2016, there were 62,174,301 shares of Ashland common stock outstanding.
About Ashland
Ashland Global Holdings Inc. (NYSE: ASH) is a premier global specialty chemicals company serving customers in a wide range of consumer and industrial markets, including adhesives, architectural coatings, automotive, construction, energy, food and beverage, personal care and pharmaceutical. At Ashland, we are 6,000 passionate, tenacious solvers - from renowned scientists and research chemists to talented engineers and plant operators - who thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Ashland also maintains a controlling interest in Valvoline Inc. (NYSE: VVV), a premium consumer-branded lubricant supplier. Visit ashland.com to learn more.
C-ASH
SM Service mark, Ashland or its subsidiaries, registered in various countries.
(TM) Trademark, Ashland or its subsidiaries, registered in various countries.
FOR FURTHER INFORMATION:
Investor Relations:
Seth A. Mrozek
+1 (859) 815-3527
[email protected]
Media Relations:
Gary Rhodes
+1 (859) 815-3047
[email protected]
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ashland Inc. via Globenewswire
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ashland Inc. (ASH) PT Raised to $70 at Wells Fargo
- ENGI Products LLC Releases The Physics of Capital Framework for Industrial Organizations
- Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share